Radiotheranostics Resources

Explore the science behind Radiotheranostics!

From nuclear medicine and radionuclides to therapeutic applications and expert insights, access trusted resources to better understand this innovative approach to cancer care.

What is Nuclear medicine?

Natural Radioactivity first appeared concomitantly to the creation of the Earth, and the radionuclides that can still be found in soil today are in fact long period Isotopes or Decay nuclides dating from original matter. As a consequence, man has always been exposed to environmental Radioactivity, whether from terrestrial or cosmic origin, and of course we continue to find these radionuclides in our food and indirectly in each of our body cells.

A Radionuclide is a substance that degrades in a very constant manner over time and emits one or several radiations. This degradation or Decay is defined by a constant, the period (or Half-life) corresponding to the time it takes for half of the remaining substance to disappear. This Half-life is specific for each Radionuclide.

The type of emitted Radiation is also specific for each Radionuclide.

There are five types of Radiation which are of interest to Nuclear medicine:

  • for diagnosis purposes, Gamma rays (γ) and beta plus (or Positron) emissions (β+) have led to the development of respectively
  • the Imaging modalities SPECT (Single Photon Emission Computed Tomography)
  • and PET (Positron Emission Tomography). Beta minus (β–), Alpha (α) radiations and soon conversion or Auger electrons are used in Metabolic Radiotherapy.

Among all the radionuclides with potential in Nuclear medicine, we shall remember those that are currently most widely used:

  • Iodine-123 and Technetium-99m as γ emitters,
  • Fluorine-18 and Gallium-68 as β+ emitters,
  • Iodine-131 and Lutetium-177 as β– emitters.
  • Newcomers will include Astatine-211 and Actinium-225 in the Alpha-emitting series
  • and Tin-117m as Conversion electron emitter.

What are Radionuclides?

Natural Radioactivity first appeared concomitantly with the creation of the Earth, and the radionuclides that can still be found in soil today are in fact long-period Isotopes or Decay nuclides dating from the original matter. As a consequence, man has always been exposed to environmental Radioactivity, whether from terrestrial or cosmic origin, and of course, we continue to find these radionuclides in our food and indirectly in each of our body cells.

A Radionuclide is a substance that degrades in a very constant manner over time and emits one or several radiations. This degradation or Decay is defined by a constant, the period (or Half-life) corresponding to the time it takes for half of the remaining substance to disappear. This Half-life is specific for each Radionuclide.

Types of radionuclides?

The type of emitted Radiation is also specific for each Radionuclide. There are five types of Radiation which are of interest to Nuclear medicine: for diagnosis purposes, Gamma rays (γ) and beta plus (or Positron) emissions (β+) have led to the development of respectively the Imaging modalities SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography). Beta minus (β–), Alpha (α) radiations and soon conversion or Auger electrons are used in Metabolic Radiotherapy.

Among all the radionuclides with potential in Nuclear medicine, we shall remember those that are currently most widely used: Iodine-123 and Technetium-99m as γ emitters, Fluorine-18 and Gallium-68 as β+ emitters, Iodine-131 and Lutetium-177 as β– emitters. Newcomers will include Astatine-211 and Actinium-225 in the Alpha-emitting series and Tin-117m as Conversion electron emitter.

Radiotherapeutics

The list of radiotherapeutics below is intended to be as exhaustive as possible. Despite our best efforts to regularly update the information, the field of radiotherapeutics is changing and evolving rapidly. Should you notice any missing molecules or wish to add some elements of precision, please contact us. This information is public. However, if you wish to use it, please mention the Oncidium foundation in reference – A very special thanks to MEDraysintell for the scientific and technical support.

Last update July 2023.

RadiotherapeuticTarget MechanismRadionuclideLigand/CarrierIndicationStatusRadiation Type
Ac-225-DOTA-SPSubstance P225AcSubstance PGlioblastomaIn Clinical developmentalpha (α)
Ac-225-DOTA-YS5CD46225AcIgG1Prostate CancerEarly stagealpha (α)
Ac-225-DOTATOCSomatostatin receptors225AcEdotreotideNeuroendocrine Tumor (NET)Early stagealpha (α)
Ac-225-DOTAZOLBones225Acn/aBone pain palliationEarly stagealpha (α)
Ac-225-FPI-1434IGF-1R225AcFPI-1434Solid TumorsIn Clinical developmentalpha (α)
Ac-225-FPI-2059NTSR1225Ac3BP-227Solid TumorsEarly stagealpha (α)
Ac-225-FPI-2068EGFR225AcFabSolid TumorsEarly stagealpha (α)
Ac-225-FPI-2265PSMA225AcPSMA-I&TProstate CancerIn Clinical developmentalpha (α)
Ac-225-Lintuzumab (Ac-225 Actimab-A™)CD33225AcLintuzumabAcute Myeloid Leukemia (AML), Colon cancerIn Clinical developmentalpha (α)
Ac-225-MTI-201Melanocortin-1225AcFabUveal CancerEarly stagealpha (α)